- Home
- OLO vs EWTX Comparison
OLO vs EWTX Comparison
Compare OLO & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLO
- EWTX
- Stock Information
- Founded
- OLO 2005
- EWTX 2017
- Country
- OLO United States
- EWTX United States
- Employees
- OLO N/A
- EWTX N/A
- Industry
- OLO Major Banks
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- OLO Finance
- EWTX Health Care
- Exchange
- OLO Nasdaq
- EWTX Nasdaq
- Market Cap
- OLO 1.7B
- EWTX 1.5B
- IPO Year
- OLO 2021
- EWTX 2021
- Fundamental
- Price
- OLO $10.28
- EWTX $14.67
- Analyst Decision
- OLO Buy
- EWTX Buy
- Analyst Count
- OLO 3
- EWTX 9
- Target Price
- OLO $10.17
- EWTX $39.89
- AVG Volume (30 Days)
- OLO 5.1M
- EWTX 781.4K
- Earning Date
- OLO 11-06-2025
- EWTX 11-06-2025
- Dividend Yield
- OLO N/A
- EWTX N/A
- EPS Growth
- OLO N/A
- EWTX N/A
- EPS
- OLO N/A
- EWTX N/A
- Revenue
- OLO $314,327,000.00
- EWTX N/A
- Revenue This Year
- OLO $20.82
- EWTX N/A
- Revenue Next Year
- OLO $17.11
- EWTX N/A
- P/E Ratio
- OLO N/A
- EWTX N/A
- Revenue Growth
- OLO 21.92
- EWTX N/A
- 52 Week Low
- OLO $4.56
- EWTX $10.60
- 52 Week High
- OLO $10.55
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- OLO 62.88
- EWTX 53.28
- Support Level
- OLO $10.24
- EWTX $14.08
- Resistance Level
- OLO $10.33
- EWTX $15.16
- Average True Range (ATR)
- OLO 0.03
- EWTX 0.70
- MACD
- OLO -0.01
- EWTX 0.01
- Stochastic Oscillator
- OLO 50.00
- EWTX 39.78
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.